136 results
8-K
EX-99.1
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the development
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
strategy, future plans and prospects, including statements regarding the company’s financial performance, the development and commercialization
8-K
EX-99.1
adkdl3tnm fl2u663zs
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
6dbjhnkgo2 1y7gur
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
qv4g0z2gp4n0t wsg72m
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
euh4sujl
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
lwbs7xok7
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
hylo027d3ivbp1s22
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
prler
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
5ms2gxhqx6x7uzip
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
5l0 4mccdzdwo70d
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm